**Molecular Basis for Leukocyte Integrin $\alpha_E\beta_7$ Adhesion to Epithelial (E)-Cadherin**

By Karen S. Taraszka,* Jonathan M.G. Higgins,* Kemin Tan,§ Didier A. Mandelbrot,*,‡ Jia-huai Wang,§ and Michael B. Brenner*

From the *Departments of Immunology and Allergy, the†Renal Division, Department of Medicine, Brigham and Women’s Hospital, and the§Dana-Farber Cancer Institute, Boston, Massachusetts 02115

Abstract

Cadherins are expressed in tissue-restricted patterns and typically mediate homophilic adhesion. Cadherins also mediate lymphocyte adhesion, providing the opportunity for lymphocyte attachment to parenchymal cells. The best characterized example of lymphocyte adhesion to a tissue-specific cell adhesion molecule, as opposed to a vascular endothelial adhesion molecule, is the interaction between integrin $\alpha_E\beta_7$ on intraepithelial lymphocytes and E-cadherin on epithelial cells. However, the molecular basis for an integrin–cadherin interaction is not well defined. Realization that the cadherin domain adopts a topology similar to the immunoglobulin (Ig) fold suggested that integrin recognition of E-cadherin might be similar to recognition of Ig superfamily ligands. Thus, we modeled domain 1 of human E-cadherin and studied the role of solvent-exposed loops that connect Ig-like core-forming $\beta$ strands. Mutational analyses localized the integrin $\alpha_E\beta_7$ recognition site to the top of domain 1 at the face formed by the BC and FG loops, a site distinct from the region recognized in intercellular adhesion molecule (ICAM)-1, -2, and -3, mucosal addressin cell adhesion molecule 1 (MAdCAM-1), vascular cell adhesion molecule 1 (VCAM-1), and fibronectin by their integrin ligands. Moreover, the integrin $\alpha_E\beta_7$ binding site is distinct from the homophilic binding site on E-cadherin. These studies provide a conceptual basis for integrin-cadherin binding and extend the model that an Ig-like fold can serve as a scaffold for recognition.

Key words: cadherins • integrins • cell adhesion • T lymphocytes • protein binding

Introduction

Although several specific adhesion molecules mediate lymphocyte adhesion to the vascular endothelium, few molecular interactions have been identified that are involved in the specific retention of lymphocytes in tissues. The best characterized tissue-specific interaction is that between integrin $\alpha_E\beta_7$ on mucosal T cells, and epithelial (E)-cadherin expressed on epithelial cells. E-cadherin has been shown to mediate T cell–epithelial cell adhesion via $\alpha_E\beta_7$ in cell–cell and cell–fusion protein adhesion assays in vitro (1, 2). Moreover, as the number of intraepithelial lymphocytes (IELs) is markedly reduced in $\alpha_E$-deficient mice, the E-cadherin–$\alpha_E\beta_7$ interaction is important in lymphocyte localization in the epithelium (3). Yet, the molecular basis for the binding of an integrin and a cadherin is not well understood.

Integrins are heterodimeric integral membrane proteins composed of noncovalently associated $\alpha$ and $\beta$ subunits. The integrin $\alpha_E$ chain contains an inserted domain (I or A) within its NH$_2$-terminal region (4). The crystal structures of the A domains of the integrin $\alpha_L$, $\alpha_M$, and $\alpha_2$ chains have been determined and reveal a metal ion binding site located at the top of the A domain, (5–9). Five of the six coordination sites for the divalent cation are contributed directly or indirectly via water by conserved residues in the...
A domain that include a linear D-X-S-X-S motif and discontinuous threonine and aspartate residues (5–9). In one crystal structure, the sixth coordination site was provided by a glutamate residue from an adjacent, symmetry-related A domain, suggesting a direct role for an acidic residue in the ligand in coordination of the metal ion (6). It has been proposed that all integrin β chains contain a similar A-like domain (6). Certain integrin ligands contain acidic residues that are critical for integrin adhesion and that are present in solvent-exposed locations accessible for integrin recognition, generally on loops connecting the strands of Ig-like domains. For example, recognition of the first Ig domains of vascular cell adhesion molecule 1 (VCAM-1) and mucosal addressin cell adhesion molecule 1 (MAdCAM-1) requires an acidic residue at the tip of the CD loop on the lower side of domain 1 (10–13), and integrin αβ2 recognition of intracellular adhesion molecule (ICAM)-1, ICAM-2, and ICAM-3 requires an acidic residue that is the last residue of the C strand on the lower side of domain 1 (14, 15).

The αβ2-E-cadherin interaction is unique among integrin ligands. Cadherins are type 1 integral membrane proteins with five extracellular homologous “cadherin” domains, a transmembrane region, and a highly conserved cytoplasmic tail, and are classically described as calcium-dependent homophilic cell adhesion molecules important in morphogenesis and tissue architecture (16). Although cadherins do not share detectable sequence homology with Ig superfamily (IgSF) members, the structural determination of the N-H-terminal domains of murine E- and neural (N)-cadherin by NMR and x-ray crystallography reveals that the overall topology of the cadherin domain consists of seven β strands that form a β barrel and is similar to the Ig fold (17–21). This realization led us to hypothesize that αβ2 might recognize E-cadherin in a manner related to how integrins recognize their IgSF counterreceptors.

Here, we model the first domain of human E-cadherin on the murine E-cadherin crystal structure. Through site-directed mutagenesis, we elucidate the face and specific residues that are the adhesion site for binding the integrin αβ2 and show that this site is distinct from that mediating homophilic cadherin adhesion. These molecular interactions provide a conceptual basis for the adhesion of leukocytes to parenchymal cells based on the expression of tissue-specific cadherins.

**Materials and Methods**

mAbs. The following mouse antihuman mAbs were used: αE7-1 (anti-αβ2, IgG2a) (22), αE7-2 (anti-αβ2, IgGl) (22), αE7-3 (anti-αβ2, IgGl) (22), E6.6 (anti-E-cadherin, IgGl) (23), HEC1-D (anti-E-cadherin, IgGl; Zymed) (24), and SHE87-8 (anti-E-cadherin, IgG2a; Zymed).

Cell Cultures. Human IEL-496 T cells were derived from intestinal IELs and maintained as described previously (2, 25). Human embryonic kidney (HEK)-293-EBNA cells (Invitrogen) were maintained in DMEM (GIBCO BRL) with 10% fetal bovine serum (FBS) at 10% CO2. Transfectants of the human chronic myelogenous leukemia cell line K562 that express αβ2 (K562-αβ2) were provided by Dr. David Erle (University of California San Francisco, San Francisco, CA) and maintained as described previously (26). Human breast epithelial cells MCF-7 (American Type Culture Collection) were grown in DMEM with 10% FBS at 10% CO2.

Construction of Mutated E-Cadherin-Fc Expression Vectors. Human E-cadherin-Fc (five extracellular domains of E-cadherin fused to the Fc portion of human IgGl) (2) was excised from pCDM8 with EcoRV and NotI and ligated into pBluescript SK II (pBS; Stratagene). Mutations were introduced by PCR using pBS-E-cadherin-Fc as a template and Pfu polymerase (Stratagene) according to the manufacturer’s recommendations with 25 cycles of 94°C for 1 min, 52°C for 2 min, 72°C for 1 min, and one cycle at 72°C for 10 min. For mutations with a nearby restriction site, PCR was performed with one primer complementary to the wild-type sequence and a second primer containing the mutation and a restriction site. Mutations to the BC loop were made with a forward primer complementary to the 5′ end of E-cadherin (hEprimV 5′-AAG TCA GTT CAG ACT CCA GCC C-3′) and a reverse primer incorporating the mutation and the Msci site (hEprimH 5′-AGC TCC TTG GCC AGT GAT GCT GTA GAA AAC CTT GCC TGC TTG GTC-3′ for E31A, hEprimAL5 5′-AGC TCC TTG GCC AGT GAT GCT GTA GAA AAC CTT GCC ATC TTG GTC-3′ for E31D, hEprimT 5′-GCT TCT TGG CCA GTG ATG CTT TGG AAA ACC GCG CCT TC-3′ for K32A, and hEprimU 5′-GCT TCT TGG CCA GTG ATG CTT TAG AAA ACC GCC TCT CTG TCT TT-3′ for K30A or K33A). The D44A mutation in the CD loop was made using a forward primer containing the Msci site, the D44A mutation (hEprim5′-ATC ACT GCT GAA GGA GCT GCC ACC CCT GT-3′) and a reverse wild-type primer (hEprimB 5′-CTC CAT TGG ATC CAC TGC-3′). E56A mutation in the BC loop was made using a forward wild-type primer (hEprimG 5′-TAC GTG TTT ACT ACC CAA CAG ATC TTC TT-3′) and a reverse primer containing the E56A mutation and the Eco57I site (hEprimS 5′-CTT CTC TAT CCA GAG GCT CTT TCG TCA CTT CCA GCC ATC TCG TTT CTT C-3′). The other mutations were introduced by overlap extension PCR (27). First, PCR was performed with a forward primer complementary to the wild-type sequence near the 5′ end of E-cadherin (hEprimV) and a reverse primer containing the mutation (hEprimO 5′-TGT AGA AAA CCT TGC CTT CTT TGT TGT AGT CGA TCT G-3′ for K25A, hEprimP 5′-TGT AGA AAA CCT TGC CTT TGT TGT TGG CGG ATT TGA TCT G-3′ for N27A, hEprimQ 5′-TGT AGA AAA CCT TGC CTT TGT TGT TGG CGG ATT TGA TCT G-3′ for S83A, and hEprimR 5′-TGT AGA AAA CCT TGC CTT TGT TGT TGG CGG ATT TGA TCT G-3′ for N86A, and hEprimAE 5′-GCT TAC GTG GAA CAA AAT CTC ATG TGC ATC GCC AAC TGC-3′ for E89A). Concurrently, PCR was performed with a forward primer complementary to the 5′ end of the primer containing the mutation (hEprimS 5′-AGA AGG CAA GGT TTT CTA CAG CAT CAC TGG CCA AGG AGC-3′ for K25A, K27A, K28A, and K30A; hEprimAD 5′-GCA GGT GAT CAT ATG GAG ATT-3′ for S83A and N86A; and hEprimAH 5′-ACT GGC CAA GGA GCT GAC ACA CCC CCT-3′ for E89A) and reverse primer located downstream (hEprimW 5′-
PCR reaction was performed using these two overlapping PCR products as the template and primers at the 5' (hEprImV) and 3' (hEprImW) ends. The PCR products were cleaved with restriction enzymes (Ncol and MscI for K27A, N25A, K28A, K30A, E31A, E31D, KEG30-32RT, and K33A; MscI and BamHI for D44A; P11M1 and Eco57I for E56A; and Ncol and SnaBI for S83A, N86A, and E89A) and ligated into pBS-E-cadherin-Fc. The PCR-amplified region of each clone was sequenced. The pBS-E-cadherin-Fc mutants were serially digested, first with NcI and Scal, and then with HindIII. The mutared E-cadherin-Fc insert was ligated into pCEP4 (Invitrogen) and cleaved with HindIII and NcI. DNA for transfections was prepared using a Qiagen Plasmid Maxi Kit.

Production of E-cadherin-Fc fusion proteins. Purified wild-type E-cadherin-Fc fusion protein was produced as described previously (2). Mutated and wild-type E-cadherin-Fc fusion protein was produced by transient transfection of HEK-293-EBNA cells with 10 μg of pCEP4-E-cadherin-Fc plasmid DNA using the CaPO₄ transfection protocol provided in the Stratagene Mammalian transfection kit. To produce the cadherin-Fc proteins, transfected cells were grown in DMEM containing 10% fetal pig serum ( Gibco BRL). After 5–10 d, the culture supernatants were harvested, filtered through a 0.2-μm membrane, and stored at 4°C.

ELISA. Recombinant soluble E-cadherin-Fc fusion proteins were quantitated in culture supernatants by ELISA. The wells of Linbro Titertek 96-well plates (ICN Flow Laboratories) were coated with goat anti-human IgG polyclonal antisera (Zymed) at 1:100,000. After washing, blots were probed with HBS 1 mM CaCl₂, pH 7.4. Subsequently, the wells were washed three times with 200 μl ml of Tris-buffered saline (TBS), 1 mM CaCl₂, pH 7.4. Subsequently, the wells were blocked with TBS 1 mM CaCl₂, 1% BSA for 2 h at room temperature. The wells were washed three times with TBS, 1 mM CaCl₂, 0.05% Tween 20. Supernatants from HEK-293-EBNA cell transfecants were incubated for 2 h at room temperature, and purified wild-type E-cadherin-Fc was used as the standard. Bound fusion protein was detected with alkaline phosphatase-conjugated goat anti-human IgG Fc-specific (Sigma Chemical Co.) antibody and Sigma 104® phosphatase substrate (Sigma Chemical Co.). The reaction was allowed to proceed for 20–40 μg/ml purified mAbs for 10 min at 4°C. Adhesion was carried out in final concentrations of 10–20 μg/ml purified mAbs.

Statistical Analysis. Using a two-sided t test and controlling for plate to plate variability, average values of cell adhesion to mutated E-cadherin-Fc fusion protein were compared with average values of cell adhesion to wild-type E-cadherin-Fc to determine whether adhesion to the mutant was significantly different from adhesion to wild-type. Using the Bonferroni conservative adjustment for a confidence limit of 95% with 13 tests, a P value of 0.05/13 or P ≤ 0.0038 was considered statistically significant. The analysis was performed using the program “SAS” for UNIX.

Modelling of human E-cadherin. Sequence alignments were performed using the Genetics Computer Group program PileUp. Human E-cadherin was modeled based on the murine E-cadherin crystal structure (available from the Protein Data Bank, http://www.rcsb.org/pdb, under accession no. 1EDH) (19). Using the program “O” (T.A. Jones, Uppsala University, and M. Kjeldgaard, Aahus University), sequence substitution of human E-cadherin was performed using the program “O” (T.A. Jones, Uppsala University, and M. Kjeldgaard, Aahus University). The structure of human E-cadherin is predicted to be similar to that of the murine E-cadherin structure.

Results

Sequence analysis and Modelling of human E-cadherin. The amino acid sequence of the first domain of human E-cadherin was aligned with that of murine E- and N-cadherin, and there did not appear to be any deletions or insertions (Fig. 1 A). Domain 1 of human E-cadherin shares 89% amino acid sequence identity with domain 1 of murine E-cadherin. Interestingly, all 11 substituted residues are solvent-exposed based on the crystal structure of the two NH₂-terminal domains of murine E-cadherin (19). Therefore, the structure of human E-cadherin is predicted to be very similar to that of murine E-cadherin. As the core structure of the β barrel is predicted to be highly conserved, we developed a model of human E-cadherin based on the murine E-cadherin structure (Fig. 1 B). This model of human E-cadherin was used to consider possible interaction sites in cadherin–integrin binding with special reference to solvent-exposed acidic residues on loop structures. The seven β strands in the cadherin domain form two antiparallel β sheets, one formed by β strands D, E, and B and the other by β strands A, G, F, and C. With-
out the conserved sheet disulfide bond present in Ig domains, the β strands in cadherin domains have a more cylindrical arrangement that has been termed a β barrel. Loops extend from and connect the β strands, and the majority of the solvent-exposed residues are located on the loops. The BC loop is exposed at the top of domain 1 of E-cadherin, contains a single turn of 310 helix, and as a whole has a high atomic mobility (18, 19). The BC loop contains two acidic residues, D29 and E31. Residue D29 is conserved among cadherin domains (Fig. 1 A). Based on our model, the side chain of D29 is predicted to point into the core of the structure and hydrogen bond to Y36. As D29 may be important in preserving the conformation of the BC loop, it was not mutated. The side chain of E31 is solvent-exposed and highly accessible at the tip of the BC loop, and thus a good candidate for integrin recognition (Fig. 1 B). The CD loop that protrudes from the lower side of the domain contains two conserved proline residues (Fig. 1 A) and assumes a helical structure termed a quasi–β helix (Fig. 1 B; 18, 19). The central residues of the BC loop of human E-cadherin, GAD44TP, share a striking similarity to the integrin binding motif, G/Q I/L E/D S/T S/P, found in the C strands of ICAM-1, ICAM-2 and ICAM-3, and in the CD loops of VCAM-1 and MAdCAM-1 (28). Based on the similarity to other integrin binding sites, the solvent-exposed D44 was considered a good candidate for integrin αEβ7 recognition. The DE loop in E-cadherin points upward and is solvent-exposed in the central portion of the domain. The side chain of E56 is also solvent-exposed and located at the tip of the DE loop, and thus also has the potential to be involved in integrin αEβ7 recognition (Fig. 1 B). The FG loop is located at the top of the molecule adjacent to the BC loop (Fig. 1 B), and there are no negatively charged residues on the tip of the FG loop of human E-cadherin (Fig. 1 A). The AB and EF loops are located at the bottom of the cadherin domain (Fig. 1 B). The acidic residues, E11 and E13, in the AB loop and acidic residues, D67 and E69, in the EF loop are predicted to be involved in binding calcium along with residues from the second cadherin domain (Fig. 1 A; 17). These residues are predicted to be important in domain–domain interactions, and thus were not selected for mutation as potential integrin binding residues.

**Effect of Mutation of the Central Acidic Residues in the BC, CD, and DE Loops of E-Cadherin on Heterophilic Adhesion to IELs.** We used a recombinant fusion protein consisting of the five extracellular domains of human E-cadherin fused to the Fc portion of human IgG1 in order to study E-cadherin loop interactions with integrin αEβ7 (2). M utants of the E-cadherin-Fc fusion protein were produced by transient transfection of HEK-293 cells as described in Materials and Methods. The concentration of E-cadherin-Fc in the culture supernatants was determined by ELISA using purified wild-type E-cadherin-Fc as a standard. Western blot analysis of the E-cadherin-Fc mutants using an anti–human IgG Fc antibody demonstrated that the products were the correct size and confirmed the results of quantitation by ELISA (data not shown). To ensure that the E-cadherin-Fc mutants were properly folded, each of the mutants was tested for the ability to support homophilic adhesion, a function that is localized to domain 1 (16; and see below). Additionally, all of the mutants were recognized by two anti–E-cadherin mAbs in ELISA (data not shown): E4.6, which blocks heterophilic adhesion (23), and HECD-1, which blocks homophilic adhesion (29).

Cell-fusion protein adhesion assays were performed to determine the function of site-directed mutants of E-cadherin-Fc in heterophilic adhesion to integrin αEβ7-bearing...
To delineate the critical loop residues of E-cadherin that mediate adhesion to \( \alpha_E \beta_7 \), acidic loop residues in E-cadherin were selected for alanine substitution based on the human E-cadherin model (above), and mutants were tested for their ability to support adhesion of IEL-derived T cells (Fig. 2). D44A and wild-type E-cadherin-Fc have similar dose–response curves, and above saturating levels of fusion protein, 59% of IELs adhered to the D44A mutant of E-cadherin-Fc fusion protein compared with 61% of IELs that adhered to wild-type E-cadherin-Fc (Fig. 2 A, ○ and ◆ are overlapping in figure, \( P \approx 0.71 \)). Thus, there was no significant difference between IEL adhesion to the E-cadherin-Fc CD loop mutant D44A and wild-type. Similarly, the DE loop mutant E56A and wild-type E-cadherin-Fc share similar dose–response curves, and at saturating levels E56A supported 60% of IEL adhesion compared with 57% for wild-type (Fig. 2 B, \( P \approx 0.67 \)). Thus, there was no significant difference between IEL adhesion to E56A and wild-type E-cadherin-Fc. In contrast to the CD and DE loop mutations that preserved \( \alpha_E \beta_7 \) adhesion to E-cadherin, the E31A mutation at the tip of the BC loop completely abolished detectable adhesion of IELs. No IELs bound to the E31A mutant, compared with 56% of IELs that bound to wild-type (Fig. 2 C, \( P \approx 0.0001 \)).

Refinement of the Heterophilic Adhesion Site. Although these studies pointed to a critical role for E31 in E-cadherin adhesion to \( \alpha_E \beta_7 \), it is unlikely that the specificity of the integrin \( \alpha_E \beta_7 \)-E-cadherin interaction is determined by a single residue. The contact between the two molecules most likely involves multiple residues that determine specificity and stabilize the interaction. Using the human E-cadherin model (Fig. 1 B), we selected additional residues with solvent-exposed side chains in the proximity of E31 for site-directed mutagenesis. In the BC loop, residues K25, N27, K28, K30, and K33 have solvent-exposed side chains in close proximity to the side chain of E31 and may be important in recognition of integrin \( \alpha_E \beta_7 \). Thus, E-cadherin-Fc fusion proteins containing mutations of these residues to alanine were produced and tested in adhesion to \( \alpha_E \beta_7 \)-expressing cells. Beginning at the NH₂ terminus of the BC loop, we found that 69% of the input IELs adhered to E-cadherin-Fc containing the K25A mutation compared with 72% of IELs that adhered to wild-type E-cadherin-Fc (Fig. 3 A, \( P \approx 0.35 \)). Continuing along the BC loop, mutants N27A, K28A, and K30A supported adhesion of 58% of the IELs that adhered to wild-type E-cadherin-Fc containing the K25A mutation with 72% of IELs that adhered to wild-type E-cadherin-Fc (Fig. 3 E, \( P \approx 0.46 \)). Thus, there were no significant differences between IEL adhesion to wild-type E-cadherin-Fc and E-cadherin-Fc mutants K25A, N27A, K28A, K30, and K33A.

Recognizing that >100-fold more human placental (P)-cadherin-Fc than E-cadherin-Fc fusion protein is required to support IEL adhesion (2), we compared the BC loops of these two ligands. The only differences between the BC loop of E-cadherin and P-cadherin are residues 30, 31, and 32 (Fig. 1 A). Thus, we substituted the central three residues of the BC loop of P-cadherin (RD31T) in place of KE31G in E-cadherin (mutant termed KEG30-32RD) to determine the effect on IEL adhesion. Even though both wild-type E-cadherin and the KEG30-32RD mutant
contain an acidic residue at position 31, the KEG30-32RDT mutation completely abolished adhesion of IELs (Fig. 3 F, P ≤ 0.0001). To distinguish the role of E31 from the flanking residues, we also constructed the conservative E31D mutation. Surprisingly, the E31D mutation also completely abolished detectable adhesion of IELs (Fig. 3 G, P ≤ 0.0001).

The FG loop is located adjacent to the BC loop at the top of the cadherin domain, suggesting that side chains of this loop might also participate in integrin binding (Fig. 1 B). Analysis of the human E-cadherin model revealed that the side chains of residues S83, N86, and E89 in the FG loop are in close proximity to the critical E31 residue in the BC loop. E-cadherin-Fc fusion protein containing the FG loop S83A mutation was found to support adhesion of 68% of the IELs compared with adhesion of 72% of the IELs to wild-type E-cadherin-Fc (Fig. 4 A, P = 0.55). E-cadherin-Fc with the N86A mutation supported adhesion of 57% of the IELs compared with adhesion of 53% of the IELs supported by wild-type E-cadherin-Fc (Fig. 4 B, P = 0.068). These results indicated that the S83A and N86A mutations did not significantly affect αεβ7-dependent adhesion of IELs to E-cadherin. E-cadherin-Fc containing the E89A mutation supported adhesion of 12% of the IELs compared with adhesion of 72% of the IELs to wild-type (Fig. 4 C), suggesting that the E89A mutation substantially diminished αεβ7-dependent IEL adhesion to E-cadherin (P = 0.0001). For easier comparison, the effect of the mutations on adhesion to IELs is summarized as the percentage of adhesion compared with wild-type (Fig. 5 A). The three mutants that revealed the greatest effect were all located in the BC loop and involved residue E31. These mutations completely abrogated adhesion to <2% of wild-type adhesion. In addition, E89A in the FG loop reduced heterophilic adhesion to
Heterophilic adhesion of K562-αEβ7 transfectants to immobilized E-cadherin-Fc is dose dependent, with maximal adhesion achieved with 0.02 μg of E-cadherin-Fc added per well. Adhesion is specific, as <1% of K562 mock transfectants bound to E-cadherin-Fc-coated wells, and <1% of K562-αEβ7 transfectants bound to IgG1-coated wells (data not shown). However, mean maximal adhesion of K562-αEβ7 transfectants to wild-type E-cadherin-Fc is 30% compared with mean maximal adhesion of IEL to wild-type E-cadherin-Fc, which is 58% (data not shown).

Heterophilic adhesion of K562-αEβ7 transfectants to mutants E31A, E31D, and KEG30-32RDT was not detectable, confirming the findings in adhesion to in vitro–cultured IEL T cells expressing αEβ7 (Fig. 5 B). E-cadherin-Fc containing K25A and K33A mutations in the BC loop supported adhesion similar to wild-type: 87% (P = 0.0113) and 104% (P = 0.36), respectively, as a percentage of adhesion to wild-type E-cadherin (Fig. 5 B). BC loop mutants N27A, K28A, and K30A only partially supported adhesion of K562-αEβ7 transfectants: 57% (P ≤ 0.0001), 79% (P ≤ 0.0001), and 53% (P ≤ 0.0001), respectively, as a percentage of adhesion to wild-type E-cadherin (Fig. 5 B). Thus, K562-αEβ7 transfectants identified additional BC loop mutations with statistically significant differences in the ability to support heterophilic adhesion compared with wild-type, namely N27A, K28A, and K30A. M utants containing the D44A change in the CD loop and the E56A change in DE loop supported heterophilic adhesion to K562-αEβ7 similar to wild-type: 105% (P ≤ 0.62) and 102% (P ≤ 0.40), respectively, like the situation for these mutations in adhesion to IELs FG loop mutants S83A and N86A partially supported heterophilic adhesion to K562-αEβ7; 80% (P ≤ 0.0001) and 86% (P ≤ 0.0017), respectively, as a percentage of adhesion to wild-type E-cadherin-Fc (Fig. 5 B). In contrast, FG loop mutant E89A did not support detectable adhesion, confirming the finding with adhesion to IELs (Fig. 5 B). In summary, the K562-αEβ7 transfectants confirmed the role of mutations noted for adhesion of IELs and identified several additional mutants with smaller but statistically significant differences in the ability to support heterophilic adhesion compared with wild-type (N27A, K28A, K30A, S83A, and N86A). For a conservative interpretation, we emphasize mutations N27A and K30A, as they resulted in the largest (>40%) reduction in αEβ7-dependent adhesion (Fig. 5 B).

Location of αEβ7. A dhesin Site on E-cadherin. W e analyzed the human E-cadherin model examining the location of residues affecting or not affecting adhesion of αEβ7-expressing cells to E-cadherin-Fc. As shown in the ribbon diagram of domain 1 of E-cadherin, the side chains of residues K25 and K33 on the BC loop and E56 on the DE loop point in approximately the same direction away from the sheet formed by the D, E, and B strands (Fig. 6 A). M utation of residues K25, K33, and E56 to alanine in E-cadherin-Fc did not affect heterophilic adhesion to IELs or K562-αEβ7 transfectants, suggesting that the integrin does not approach E-cadherin at the DEB sheet. The side chains of residues D44 on the CD loop and S83 and N86 on the FG loop are

20% of wild-type. In contrast, the other mutations located in the remainder of the BC and FG loop as well as the CD and DE loops supported >82% of wild-type adhesion.

A dditional M utations Reduce Heterophilic A dhesion of K562-αEβ7 T ransfectants to E-C adherin. T o confirm the importance of E31 on the top of the BC loop and E89 on the FG loop in IEL adhesion to E-cadherin-Fc and to identify additional residues involved in heterophilic adhesion, we examined the adhesion of K562-αEβ7 transfectants to the panel of E-cadherin-Fc mutants under the same conditions used to study heterophilic adhesion of IEL T cells. W e hypothesized that K562-αEβ7 transfectants might identify other residues involved in heterophilic adhesion, as K562-αEβ7 transfectants adhere less strongly to E-cadherin-Fc under the same conditions. Similar to IEL adhesion, heterophilic adhesion of K562-αEβ7 transfectants to immobilized E-cadherin-Fc is dose dependent, with maximal adhesion achieved with 0.02 μg of E-cadherin-Fc added per well. Adhesion is specific, as <1% of K562 mock transfectants bound to E-cadherin-Fc-coated wells, and <1% of K562-αEβ7 transfectants bound to IgG1-coated wells (data not shown). However, mean maximal adhesion of K562-αEβ7 transfectants to wild-type E-cadherin-Fc is 30% compared with mean maximal adhesion of IEL to wild-type E-cadherin-Fc, which is 58% (data not shown).

Heterophilic adhesion of K562-αEβ7 transfectants to mutants E31A, E31D, and KEG30-32RDT was not detectable, confirming the findings in adhesion to in vitro–cultured IEL T cells expressing αEβ7 (Fig. 5 B). E-cadherin-Fc containing K25A and K33A mutations in the BC loop supported adhesion similar to wild-type: 87% (P = 0.0113) and 104% (P = 0.36), respectively, as a percentage of adhesion to wild-type E-cadherin (Fig. 5 B). BC loop mutants N27A, K28A, and K30A only partially supported adhesion of K562-αEβ7 transfectants: 57% (P ≤ 0.0001), 79% (P ≤ 0.0001), and 53% (P ≤ 0.0001), respectively, as a percentage of adhesion to wild-type E-cadherin (Fig. 5 B). Thus, K562-αEβ7 transfectants identified additional BC loop mutations with statistically significant differences in the ability to support heterophilic adhesion compared with wild-type, namely N27A, K28A, and K30A. M utants containing the D44A change in the CD loop and the E56A change in DE loop supported heterophilic adhesion to K562-αEβ7 similar to wild-type: 105% (P ≤ 0.62) and 102% (P ≤ 0.40), respectively, like the situation for these mutations in adhesion to IELs FG loop mutants S83A and N86A partially supported heterophilic adhesion to K562-αEβ7; 80% (P ≤ 0.0001) and 86% (P ≤ 0.0017), respectively, as a percentage of adhesion to wild-type E-cadherin-Fc (Fig. 5 B). In contrast, FG loop mutant E89A did not support detectable adhesion, confirming the finding with adhesion to IELs (Fig. 5 B). In summary, the K562-αEβ7 transfectants confirmed the role of mutations noted for adhesion of IELs and identified several additional mutants with smaller but statistically significant differences in the ability to support heterophilic adhesion compared with wild-type (N27A, K28A, K30A, S83A, and N86A). For a conservative interpretation, we emphasize mutations N27A and K30A, as they resulted in the largest (>40%) reduction in αEβ7-dependent adhesion (Fig. 5 B).

Location of αEβ7. A dhesin Site on E-cadherin. W e analyzed the human E-cadherin model examining the location of residues affecting or not affecting adhesion of αEβ7-expressing cells to E-cadherin-Fc. As shown in the ribbon diagram of domain 1 of E-cadherin, the side chains of residues K25 and K33 on the BC loop and E56 on the DE loop point in approximately the same direction away from the sheet formed by the D, E, and B strands (Fig. 6 A). M utation of residues K25, K33, and E56 to alanine in E-cadherin-Fc did not affect heterophilic adhesion to IELs or K562-αEβ7 transfectants, suggesting that the integrin does not approach E-cadherin at the DEB sheet. The side chains of residues D44 on the CD loop and S83 and N86 on the FG loop are
Residues that do not substantially affect adhesion to IELs or K562-αβ7 transfectants, suggesting that the integrin does not approach E-cadherin at the CFG face. In contrast, the side chains of residues N27, K30, and E31 on the BC loop as well as E89 on the FG loop are highly solvent-exposed at the top of the molecule on the face formed by the BC and FG loops (Fig. 6 A). Mutation of E31 and E89 severely diminished heterophilic adhesion of both IEL and K562-αβ7 transfectants. Mutations N27A, K28A, and K30A had statistically significant reductions in adhesion to K562-αβ7 transfectants, and N27A and K30A reduced K562-αβ7 transfectant adhesion >40%.

A surface diagram of E-cadherin in the same orientation as the ribbon diagram in Fig. 6 A more clearly demonstrates the location of the side chains that were mutated (Fig. 6 B). The side chains of residues N27, K30, E31, and E89, which are involved in adhesion to αβ7, are shown in red. Despite the fact the implicated residues come from different loops, they are located on the same face (Fig. 6 B). Residues that do not substantially affect adhesion to αβ7 are shown in blue. Rotation of the surface diagram 180° on a vertical axis demonstrates that residues on the opposite side are not involved in adhesion to αβ7 (Fig. 6 C). Therefore, it is likely that the integrin αβ7 approaches domain 1 of human E-cadherin at the face formed by the BC and FG loops.

Analysis of the three-dimensional human E-cadherin model suggests that the side chains of residues N27, K30, and E31 protrude upward and could directly interact with the integrin (partially illustrated in Fig. 6 A). Residue E89 likely forms interactions with one or both residues, S26 and K28. E89 has the potential to form a salt bridge with the main chain amide of K28, similar to the E89/R28 pair observed in murine E-cadherin (19). E89 might also form a hydrogen bond with residue S26. These interactions would serve to stabilize the BC loop that presents residues N27, K30, and E31 for integrin recognition. In summary, mutational analyses of the NH2-terminal domain of human E-cadherin identified a localized group of exposed residues at the top of the domain that are likely to be part of the integrin αβ7 binding site either by directly binding to the integrin or by supporting the conformation of the integrin binding residues.

Homophilic Adhesion of E-Cadherin-Fc Mutants. We tested the ability of E-cadherin-Fc and its mutants to support homophilic adhesion of E-cadherin–expressing MCF-7 breast epithelial cells. Adhesion of MCF-7 cells to E-cadherin-Fc was dose dependent, with maximal adhesion of 40% of cells bound with 0.02 μg of E-cadherin–Fc added per well (Fig. 7, ♦), whereas adhesion to human IgG1 was not observed (Fig. 7, □). Confirming the specificity of this adhesion assay, we found that the adhesion of MCF-7 cells to E-cadherin-Fc was blocked by anti–E-cadherin mAbs HEC-D1 and SHE78-7, but not by isotype-matched control mAbs against αβ7, αE7-1, and αE7-2 (data not shown), and the interaction did not require the presence of magnesium or manganese.

The E-cadherin-Fc mutants were tested in homophilic adhesion to MCF-7 epithelial cells to demonstrate that the mutants were functionally folded and to determine whether the heterophilic adhesion site for αβ7 is distinct from the homophilic site for E-cadherin. E-cadherin-Fc mutations that completely abrogated IEL adhesion did not affect homophilic adhesion (Fig. 7). E31A E-cadherin-Fc supported homophilic adhesion of 41% of the MCF-7 cells (Fig. 7 A), KEG30-32RD E-cadherin-Fc supported homophilic adhesion of 38% of the MCF-7 cells (Fig. 7 B), and E31D E-cadherin-Fc supported homophilic adhesion of 41% of the MCF-7 cells (Fig. 7 C), compared with adhesion of 44% of the MCF-7 cells to wild-type E-cadherin-Fc. Thus, there were no significant differences between MCF-7 homophilic adhesion to wild-type E-cadherin-Fc and E-cadherin-Fc mutants E31A, KEG30-32RD DT, and E31D, de-
sparm the effect these mutations revealed in heterophilic adhesion. The ability of these E-cadherin mutants to function in homophilic adhesion confirms that these loop mutations did not affect proper folding of the cadherin domain and that the heterophilic E89 adhesion site is distinct from the homophilic E-cadherin adhesion site.

Figure 8 summarizes the effect of the mutations on homophilic adhesion to saturating amounts of mutated E-cadherin-Fc relative to wild-type E-cadherin-Fc, as described in the legend to Fig. 5. Results are shown as the mean \( \pm 1 \) SD of two independent experiments in which each condition was performed in triplicate. Using a two-sided t test, statistically significant differences were observed between homophilic adhesion to wild-type E-cadherin-Fc and K25A (\( P \leq 0.0003 \)), N27A (\( P \leq 0.0001 \)), and E89A (\( P \leq 0.0001 \)).

K33A) and wild-type. Mutants K28A, K30A, and K33A supported homophilic adhesion 94, 99, and 91% as well as wild-type E-cadherin, respectively. Mutants D44A in the CD loop and E56A in the DE loop supported homophilic adhesion 94 and 90% as well as wild-type E-cadherin-Fc. Mutants S83A and N86A on the FG loop and N86A also supported wild-type levels of homophilic adhesion: 105 and 93%, respectively. Homophilic adhesion supported by mutants D44A, E56A, S83A, and N86A is not significantly different from adhesion supported by wild-type. In contrast, E-cadherin-Fc containing the E89A mutation on the G strand supported only 2% of the homophilic adhesion observed for wild-type E-cadherin (\( P \leq 0.0001 \)), similar to its inability to support heterophilic adhesion. As the E89A mutant was efficiently secreted and recognized by two anti-E-cadherin mAbs, it remains likely that it is properly folded and has a role in both heterophilic and homophilic adhesion.

Although we have not specifically addressed the homophilic adhesion site, several of the residues we mutated have been implicated in homophilic adhesion in previous studies. Mutational analyses localize the homophilic binding site to domain 1 of E-cadherin and homophilic adhesion specificity determining residues to serine residues on either side of the HAV sequence at the end of the F strand: S78 and S83 (16). Simultaneous mutation of both S78 and S83 in E-cadherin to the corresponding residues in P-cadherin does not abolish calcium-dependent homophilic cell aggregation, but allows cadherin transfectants to aggregate with both E- and P-cadherin (16). In agreement, our results showed that point mutation of S83A does not diminish homophilic adhesion. The homophilic adhesion interface suggested by the adhesion dimer in the N-cadherin domain 1 crystal structure includes interactions between the C′ strand and C′ strand (prime indicates that the structure comes from the adjacent molecule), reciprocal contact between the DE loop and FG′ loop, and the CD loop to CD′ loop interactions (18). D44 is the only residue we mutated that is present at the homophilic adhesion in-
face. Mutation of D44A did not diminish homophilic adhesion, suggesting that either the loss of D44’s contribution is not significant enough to diminish homophilic adhesion because of the complexity of the homophilic adhesive interaction or the adhesion dimer seen in the crystal structure may not be the physiological interface.

Previous studies suggest that homophilic adhesion requires dimerization (30, 31). However, controversy exists over which part of the cadherin domain is involved in cis-dimerization (18–20). In our study, mutation of residues K25, N27, and E89 significantly diminished homophilic adhesion. As E-cadherin-Fc mutants K25A and N27A exhibit near wild-type adhesion to IELs, they are most likely functionally folded. As can be observed in Fig. 6 B, the residues that disrupt homophilic adhesion are located on the same face. These residues could affect homophilic adhesion by directly being part of the homophilic binding site or indirectly by contributing to cis-dimerization of E-cadherin. Residues K25, N27, and E89 are located at the cis-dimer interface observed in the murine N-cadherin domain 1 crystal structure (18) and have the potential to support cis-dimerization. Thus, we propose that mutations K25, N27, and E89 indirectly affect homophilic adhesion by interfering with cis-dimerization. This interpretation supports a physiological role for the cis-dimer in homophilic adhesion.

Discussion

A well-defined feature of integrin ligands is the presence of an aspartic acid or glutamic acid residue that is essential for integrin adhesion. The critical acidic residue in the ligand may provide a coordination site for the divalent cation that is essential for integrin adhesion (6). Our first approach was to mutate solvent-exposed acidic residues on the various loops of human E-cadherin to localize integrin recognition to a particular loop. We selected potential residues from our model of human E-cadherin based on the crystal structure of murine E-cadherin (19). Mutational analyses of the exposed acidic residues on the BC, CD, and DE loops localized the $\alpha_\beta_\gamma$ binding site to E31 in the BC loop of domain 1. This result is consistent with a previous analysis of acidic loop residues in murine E-cadherin using $\alpha_\beta_\gamma$-expressing cells adhering to L cell transfectants expressing murine E-cadherin mutants (32). We further analyzed the role of the BC loop in determining the specificity of the E-cadherin interaction with $\alpha_\beta_\gamma$32R with the increase in the critical acidic residue on the C strand of domain 1 of ICAM-1 E34D almost completely abrogated binding to $\alpha_\beta_\gamma$32R in a cell-free system (36). These previous studies suggest that the critical acidic residue on another acidic residue has little effect on $\alpha_\beta_\gamma$ recognition, but almost entirely abrogates recognition by $\alpha_\beta_\gamma$ and $\alpha_\beta_\gamma$. Here, the E31D E-cadherin-Fc mutation abrogated adhesion of IELs and K562-$\alpha_\beta_\gamma$32R transfectants, suggesting that $\alpha_\beta_\gamma$ has remarkably fine specificity for the length of the side chain of glutamic acid residue 31 in E-cadherin (Fig. 5). Analysis of the murine E-cadherin crystal structure reveals that there is one hydrogen bond between the main chain carbonyl group of residue 28 (R28 in murine, and K28 in human E-cadherin) and the main chain amide group of residue 32 (T32 in murine, and G32 in human E-cadherin). It is likely that this hydrogen bond will make the tip of the BC loop assume a rigid conformation so that the key residue E31 can be oriented correctly for binding to the integrin, potentially the MIDAS metal center. Moreover, we have also noticed a minihydrophobic core between the BC and FG loops, centered around V34, which should further stabilize the BC loop. This minihydrophobic core includes V88, A80, and Y36, as well as those aliphatic portions of other residues like K28; all of these residues are conserved. There is one more hydrogen bond in this region between the hydroxyl group of Y36 and the main chain amide group of residue 32 (T32 in murine, and G32 in human E-cadherin). It is likely that this hydrogen bond will make the tip of the BC loop assume a rigid conformation so that the key residue E31 can be posed in the correct configuration for binding to the integrin, potentially the MIDAS metal center. Moreover, we have also noticed a minihydrophobic core between the BC and FG loops, centered around V34, which should further stabilize the BC loop. This minihydrophobic core includes V88, A80, and Y36, as well as those aliphatic portions of other residues like K28; all of these residues are conserved. There is one more hydrogen bond in this region between the hydroxyl group of Y36 and the main chain amide group of S26. Although the overall atomic mobility of the BC loop in the murine E- and N-cadherin crystal structure is high with respect to the core (18, 19), these interactions serve to make the long BC loop rigid with respect to itself. From an energetic point of view, a rigid loop is more favorable during the ligand binding interaction. This may explain why the conservative E31D mutation abolishes adhesion. If the key binding motif is in a very delicate conformation designed for integrin binding, even the size of the one methyl group difference between glutamate and aspartate could be significant.
Our mutational analyses of selected residues with solvent-exposed side chains towards the top of E-cadherin domain 1 revealed that the side chains of N27, K30, E31, and E89 are important for integrin αEβ7 recognition. Modeling of the position of these side chains in human E-cadherin revealed that they are all located on the same face formed by the BC and FG loops at the top of domain 1 (Fig. 6 B). As previously discussed, these residues may directly interact with the integrin αEβ7 or may be important in maintaining the conformation of the residues that directly contact the integrin.

The integrin ligands ICAM-1, -2, -3, VCAM-1, and MAdCAM-1 belong to the IgSF. Although the tenth type III repeat of fibronectin and E-cadherin lack the sequence homology and conserved disulfide bonds to be considered an Ig fold, both of these domains share an Ig-like sandwich topology consisting of two β sheets made up of three or four antiparallel β strands (18, 19, 38). This β sandwich topology appears to be a conserved scaffold in integrin recognition. However, our studies emphasize that integrins use different exposed surfaces for recognition of different ligands. In MAdCAM-1 and VCAM-1, the critical acidic residue is present at the tip of the CD loop that protrudes from the side on the lower half of domain 1 (Fig. 9; 10–13, 28, 33, 34, 39–41). In contrast, in the ICAMs the acidic residue critical for integrin recognition is located at the end of the C strand on a flat recognition surface located on the lower side of domain 1 (Fig. 9; 14, 15, 36, 42–46). The binding site for integrins α5β1, αIIbβ3, and αVβ3 on fibronectin is the RGD sequence on an extended FG loop of the tenth type III repeat (Fig. 9; 38, 47). In contrast, αEβ7 recognizes E-cadherin at the top of the Ig-like cadherin first domain (Fig. 9). The critical acidic residue E31 is located at the very tip of the outwardly extended BC loop, and the integrin recognition surface contains residues from the BC and the adjacent FG loop. The local conformation around the critical acidic residue E31 in E-cadherin is most similar to the conformation of the corresponding FG loop in fibronectin. In conclusion, integrin recognition of E-cadherin extends the general paradigm that Ig-like folds serve as a scaffold for integrin recognition, but is unique in using the BC loop at the top of the domain (Fig. 9).

Importantly, while the three mutants involving E31 (E31A, KEG30-32RDT, and E31D) did not support detectable heterophilic adhesion, they did support homophilic adhesion of cells expressing wild-type E-cadherin. These results are the first direct evidence that the heterophilic adhesion site on E-cadherin for αEβ7 is distinct from the homophilic E-cadherin–E-cadherin adhesion site. This finding is consistent with previous studies examining the homophilic adhesion site and localizing it to the face formed by the C strand, D strand, and FG loop and in particular to residues at the COOH terminus of the F strand and in the FG loop (16, 18, 48). As the E-cadherin residues critical for heterophilic adhesion to αEβ7 are distinct from those required for homophilic adhesion, it is possible to block heterophilic adhesion selectively while preserving E-cadherin’s homophilic function. The analyses of αEβ7 recognition of E-cadherin suggest that blockade of this interaction may be similar in molecular terms to that of other integrin-IgSF interactions. The current data provide both the conceptual basis and suitable assay systems to identify therapeutic inhib-
Our data suggest that the potential exists to design therapeutics that selectively block the E-cadherin–αEβ7 interaction and do not disrupt E-cadherin homophilic adhesion. Integrin αEβ7 is expressed on nearly all T cells localized in the epithelium, as well as on certain mast cells and dendritic cells (22, 49, 50). Agents that block the interaction of αEβ7 expressing cells with E-cadherin–expressing epithelium could be useful therapeutics in mucosal inflammatory conditions such as inflammatory bowel disease.

We thank Dr. Lawren Daltroy for his guidance with the statistical analysis, and Dr. Uliike Strauch for her help in maintaining the K562 transfectants (both of the Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital).

This work was supported by National Institutes of Health grants to M.B. Brenner, HL48675 (to J.H. Wang), and AI01212 (to D.A. Mandelbrot), and by a Welcome Trust International Prize Traveling Research Fellowship and a Cohn's and Colitis Foundation of America Fellowship (to J.M.G. Higgins).

Submitted: 25 October 1999
Revised: 3 January 2000
Accepted: 17 January 2000

References

1. Cepek, K.L., C.M. Parker, J.L. Madara, and M.B. Brenner. 1993. Integrin αEβ7 mediates adhesion of T lymphocytes to epithelial cells. J. Immunol. 150:3459–3470.

2. Higgins, J.M.G., D.A. Mandelbrot, S.K. Shaw, G.J. R ussell, E.A. Murphy, Y.T. Chen, W.J. Nelson, C.M. Parker, and M.D. Brenner. 1998. Direct and regulated interaction of integrin αEβ7 with E-cadherin. J. Cell Biol. 140:197–210.

3. Schoen, M.P., A. Arya, E.A. Murphy, C.A. Adams, U.G. Strauch, W. Agace, J. Marsal, J.P. Donohue, J. Her, D.R. Deier, et al. 1999. Mucosal T lymphocyte numbers are selectively reduced in integrin αE (CD103)-deficient mice. J. Immunol. 162:6641–6649.

4. Shaw, S.K., K.L. Cepek, E.A. Murphy, G.J. R ussell, M.B. Brenner, and C.M. Parker. 1994. Molecular cloning of the human mucosal lymphocyte integrin αEβ7 subunit. Unusual structure and restricted RNA distribution. J. Biol. Chem. 269:6016–6025.

5. Q. U., A., and D.J. Leahy. 1995. Crystal structure of the I-domain from the CD11a/CD18 (LFA-1, αEβ2) integrin. Proc. Natl. Acad. Sci. USA. 92:10277–10281.

6. Lee, J.O., P. Rieu, M.A. Arnoult, and R. Liddington. 1995. Crystal structure of the A domain from the α subunit of integrin CR3 (CD11b/CD18). C. Cell. 80:631–638.

7. Q. U., A., and D.J. Leahy. 1996. The role of the divergent cation in the structure of the I domain from the CD11a/CD18 integrin. Structure. 4:931–942.

8. Emsley, J., S.L. King, J.M. Bergelson, and R.C. Liddington. 1997. Crystal structure of the I domain from integrin αEβ7. J. Biol. Chem. 272:28512–28517.

9. Baldwin, E.T., R.W. Sarver, G.L. Bryant, K.A. Curry, M.B. Fairbanks, B.C. Finzel, R.L. Garlick, R.L. Heinrikson, N.C. Horton, L.L. Kelley, et al. 1998. Cation binding to the integrin CD11b I domain and activation model assessment. Structure. 6:923–935.

10. Tan, K., J.M. Casasnovas, J.H. Liu, M.J. Briskin, T.A. Springer, and J.H. Wang. 1998. The structure of immunoglobulin superfamilies domains 1 and 2 of MAdCAM-1 reveals novel features important for integrin recognition. Structure. 6:793–801.

11. Viney, J.L., S. Jones, H.H. Chiu, B. Lagrimac, M.E. R enz, L.G. Presta, D. Jackson, K.J. Hillan, S. Lew, and S. Fong. 1996. Mucosal addressin cell adhesion molecule-1: a structural and functional analysis demarcates the integrin binding motif. J. Immunol. 157:2488–2497.

12. Jones, E.Y., K. Harlos, M.J. Bottomley, R.C. Robinson, P.C. Driscoll, R.M. Edward, J.M. Clements, T.J. Dudgeon, and D.I. Stuart. 1995. Crystal structure of an integrin-binding fragment of vascular cell adhesion molecule1 at 1.8 Å resolution. Nat.ure. 373:539–544.

13. Vonderheide, R.H., T.F. Tedder, T.A. Springer, and D.E. Staunton. 1994. Residues within a conserved amino acid motif of domains 1 and 4 of VCAM-1 are required for binding to VLA-4. J. Biol. Chem. 269:2115–2122.

14. Casasnovas, J.M., T.A. Springer, J.H. Liu, S.C. Harrison, and J.H. Wang. 1997. Crystal structure of ICAM-2 reveals a distinct integrin recognition surface. Nat.ure. 387:312–315.

15. Staunton, D.E., M.L. Dustin, H.P. Erickson, and T.A. Springer. 1990. The arrangement of the immunoglobulin-like domains of ICAM-1 and the binding sites for LFA-1 and rhinovirus. Cell. 61:243–254.

16. Nose, A., K. Tsugi, and M. Takeichi. 1990. Localization of the specificity determining sites in cadherin cell adhesion molecules. Cell. 61:147–155.

17. Overduin, M., T.S. Harvey, S. Bagby, K.I. Tong, P. Yau, M. Takeichi, and M. Ikura. 1995. Solution structure of the epithelial cadherin domain responsible for selective cell adhesion. Science. 267:386–389.

18. Shapiro, L., A.M. Fannon, P.D. Kwong, A. Thompson, M.S. Lehmann, G. Gruebel, J.F. Legrand, J. Alsnield, D.R. Colman, and W. Hendrickson. 1995. Structural basis of cell-cell adhesion by cadherins. Nat.ure. 374:327–337.

19. Nagar, B., M. Overduin, M. Ikura, and J.M. Rini. 1996. Structural basis of calcium-induced E-cadherin rigidification and dimerization. Nat.ure. 380:360–364.

20. Tamura, K., W.S. Shan, W.A. Hendrickson, D.R. Colman, and L. Shapiro. 1998. Structure-function analysis of cell adhesion by neural (N-) cadherin. Nat.ure. 20:1152–1163.

21. Pertz, O., T. Dvorak, T. Koch, C. Fasaur, A. Brancaccio, and J. Engel. 1999. A new crystal structure, Ca2+-dependence and mutational analysis reveal molecular details of E-cadherin homoaespecies. EMBO J. Eur. Mol. Biol. Org. J. 18:1738–1747.

22. R ussell, G.J., C.M. Parker, K.L. Cepek, D.A. Mandelbrot, A. Sood, E. Mizoguchi, E.C. Ebert, M.B. Brenner, and A.K. Bhan. 1994. Distinct structural and functional epitopes of the αEβ7 integrin. Eur. J. Immunol. 24:2832–2841.

23. Cepek, K.L., S.K. Shaw, C.M. Parker, G.J. R ussell, J.S. Morrow, D.L. R imm, and M.B. Brenner. 1994. Adhesion between epithelial cells and T lymphocytes mediated by E-cadherin and the αEβ7 integrin. Nat.ure. 372:190–193.

24. Shimoyama, Y., T. Yoshida, M. Terada, Y. Shimoseko, O. Abe, and S. Hirohashi. 1989. Molecular cloning of a human Ca2+-dependent cell-cell adhesion molecule homologous to mouse placental cadherin: its low expression in human placental tissues. J. Cell Biol. 109:1787–1794.

25. R ussell, G.J., C.M. Parker, A. Sood, E. Mizoguchi, E.C. Ebert, A.K. Bhan, and M.B. Brenner. 1996. P126 (CDw101), a costimulatory molecule preferentially expressed on mucosal T lymphocytes. J. Immunol. 157:3366–3374.
26. Abitorabi, M.A., R.K. Pachynaki, R.E. Ferrando, M. Tisdwell, and D.J. Erle. 1997. Presentation of integrins on leukocyte microvilli: a role for the extracellular domain in determining membrane localization. J. Cell Biol. 139:563–571.

27. Ho, S.N., H.D. Hunt, R.M. Horton, J.K. Pullen, and L.R. Pease. 1989. Site-directed mutagenesis by overlap extension using the polymerase chain reaction. Gene 77:51–59.

28. Briskin, M.J., L. Rott, and E.C. Butcher. 1996. Structural requirements for mucosal vascular addressin binding to its lymphocyte receptor αββ. Common themes among integrin-Ig family interactions. J. Immunol. 156:719–726.

29. Watabe, J., A. Nagafuchi, S. Tsukita, and M. Takeichi. 1994. Arrangement of domains, and amino acid residues required for binding of vascular cell adhesion molecule-1 to its counter-receptor VLA-4 (αββ). J. Cell Biol. 124:601–608.

30. Leahy, D.J., I. Aukhil, and H.P. Erickson. 1996. Structure of a four-domain segment of human fibronectin encompassing the RGD loop and synergy region. Cell 84:155–164.

31. Wang, J., and T.A. Springer. 1998. Structural specializations of immunoglobulin superfamily members for adhesion to integrins and viruses. Immunol. Rev. 163:197–215.

32. Leahy, D.J., I. Aukhil, and H.P. Erickson. 1996. 2.0 Å crystal structure of a four-domain segment of human fibronectin encompassing the RGD loop and synergy region. Cell 84:155–164.

33. Wang, J.H., R.B. Pepinsky, T. Stehle, J.H. Liu, M. Karpusas, B. Browning, and L. O'sborn. 1995. The crystal structure of an N-terminal two-domain fragment of vascular cell adhesion molecule 1 (VCAM-1): a cyclic peptide based on the domain 1 C-D loop can inhibit VCAM-αββ interaction. Proc. Natl. Acad. Sci. USA. 92:5714–5718.

34. O'sborn, L., C. Vassallo, and C.D. Benjamin. 1992. Activated endothelium binds lymphocytes through a novel binding site in the alternatively spliced domain of vascular cell adhesion molecule-1. J. Exp. Med. 176:99–107.

35. Chiu, H.H., D.T. Crowe, M.E. Renz, L.G. Presta, S. Jones, I.L. Weissman, and S. Fong. 1995. Similar but nonidentical amino acid residues on vascular cell adhesion molecule-1 are involved in the interaction with αββ and αββ under different activity states. J. Immunol. 155:5257–5267.

36. Holness, C.L., P.A. Bates, A.J. Little, C.D. Buckley, A. McDowall, D. Bossy, N. Hogg, and D.L. Simmons. 1995. Analysis of the binding site on ICAM-1 for its receptor, leukocyte function-associated antigen 1. J. Cell Biol. 127:30909–30915.

37. Wang, J., and T.A. Springer. 1998. Structure of a two-domain fragment of human ICAM-1 suggests how it functions as a rhinovirus receptor and as an LFA-1 integrin ligand. Proc. Natl. Acad. Sci. USA. 95:4140–4145.

38. Casanova, J.M., T. Stehle, J.H. Lie, J.H. Wang, and T.A. Springer. 1998. A dimeric crystal structure for the N-terminal two domains of intercellular adhesion molecule-1. Proc. Natl. Acad. Sci. USA. 95:4134–4139.

39. Blaschuk, O., R. Sullivan, S. David, and Y. Pouliot. 1990. Identification of a cadherin cell adhesion recognition sequence. Dev. Biol. 139:227–229.

40. Smith, T.J., L.A. Ducharme, S.K. Shaw, C.M. Parker, M.B. Brenner, P.J. Kilshaw, and J.H. Weis. 1994. Murine M290 integrin expression modulated by mast cell activation. Immunity 1:393–403.

41. Klickstein, L.B., M.R. York, A.R. de Fougerolles, and T.A. Springer. 1996. Localization of the binding site of intercellular adhesion molecule-3 (ICAM-3) for lymphocyte function-associated antigen-1 (LFA-1). J. Biol. Chem. 271:23920–23927.

42. Hynes, R.O. 1992. Integrins: versatility, modulation, and signaling in cell adhesion. C. el. 69:11–25.

43. Blaschuk, O., R. Sullivan, S. David, and Y. Pouliot. 1990. Identification of a cadherin cell adhesion recognition sequence. Dev. Biol. 139:227–229.

44. Smith, T.J., L.A. Ducharme, S.K. Shaw, C.M. Parker, M.B. Brenner, P.J. Kilshaw, and J.H. Weis. 1994. Murine M290 integrin expression modulated by mast cell activation. Immunity 1:393–403.

45. Blaschuk, O., R. Sullivan, S. David, and Y. Pouliot. 1990. Identification of a cadherin cell adhesion recognition sequence. Dev. Biol. 139:227–229.

46. Blaschuk, O., R. Sullivan, S. David, and Y. Pouliot. 1990. Identification of a cadherin cell adhesion recognition sequence. Dev. Biol. 139:227–229.

47. Holness, C.L., P.A. Bates, A.J. Little, C.D. Buckley, A. McDowall, D. Bossy, N. Hogg, and D.L. Simmons. 1995. Analysis of the binding site on ICAM-1 for its receptor, leukocyte function-associated antigen 1. J. Cell Biol. 127:30909–30915.

48. Blaschuk, O., R. Sullivan, S. David, and Y. Pouliot. 1990. Identification of a cadherin cell adhesion recognition sequence. Dev. Biol. 139:227–229.

49. Blaschuk, O., R. Sullivan, S. David, and Y. Pouliot. 1990. Identification of a cadherin cell adhesion recognition sequence. Dev. Biol. 139:227–229.